Preferential Accumulation of $^{14}$C-\textit{N}-Glycolylneuraminic Acid over $^{14}$C-\textit{N}-Acetylneuraminic Acid in the Rat Brain after Tail Vein Injection

Risa Taguchi$^{1\ast}$, Akira Minami$^{1\ast}$, Yukino Matsuda$^{1}$, Tadanobu Takahashi$^{1}$, Tadamune Otsubo$^{2}$, Kiyoshi Ikeda$^{2}$, Takashi Suzuki$^{1}$

$^{1}$ Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan, $^{2}$ Department of Organic Chemistry, School of Pharmaceutical Sciences, Hiroshima International University, Hiroshima, Japan

* These authors contributed equally to this work.

\textit{OPEN ACCESS}

\textbf{Citation:} Taguchi R, Minami A, Matsuda Y, Takahashi T, Otsubo T, Ikeda K, et al. (2015) Preferential Accumulation of $^{14}$C-\textit{N}-Glycolylneuraminic Acid over $^{14}$C-\textit{N}-Acetylneuraminic Acid in the Rat Brain after Tail Vein Injection. PLoS ONE 10(6): e0131061. doi:10.1371/journal.pone.0131061

\textbf{Editor:} Roger Chammas, Universidade de São Paulo, BRAZIL

\textbf{Received:} April 13, 2015

\textbf{Accepted:} May 28, 2015

\textbf{Published:} June 22, 2015

\textbf{Copyright:} © 2015 Taguchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\textbf{Data Availability Statement:} All relevant data are within the paper.

\textbf{Funding:} This work was supported by a Grant-in-Aid for Young Scientists (B) (KAKENHI; no. 24790080) (A.M.), a Scientific Research Grant from the Amano Foundation of Industrial Technology (A.M.) and a Sasakawa Scientific Research Grant from the Japan Science Society (R.T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

\textbf{Abstract}

The two main molecular species of sialic acid existing in nature are \textit{N}-acetylneuraminic acid (Neu5Ac) and \textit{N}-glycolylneuraminic acid (Neu5Gc). Neu5Ac is abundant in mammalian brains and plays crucial roles in many neural functions. In contrast, Neu5Gc is present only at a trace level in vertebrate brains. The brain-specific suppression of Neu5Gc synthesis, which is a common feature in mammals, suggests that Neu5Gc has toxicity against brain functions. However, in vivo kinetics of Neu5Gc in the whole body, especially in the brain, has not been studied in sufficient detail. To determine the in vivo kinetics of Neu5Gc, $^{14}$C-Neu5Gc was enzymatically synthesized and injected into rat tail veins. Although most of $^{14}$C-Neu5Gc was excreted in urine, a small amount of $^{14}$C-Neu5Gc was detected in the brain. Brain autoradiography indicated that $^{14}$C-Neu5Gc was accumulated predominantly in the hippocampus. $^{14}$C-Neu5Gc transferred into the brain was incorporated into gangliosides including GM1, GD1a, GD1b, GT1b and GQ1b. Reduction of $^{14}$C-Neu5Gc after intracerebroventricular infusion was slower than that of $^{14}$C-Neu5Ac in the brain and hippocampus. The results suggest that Neu5Gc is transferred from blood into the brain across the blood brain barrier and accumulates in the brain more preferentially than does Neu5Ac.

\textbf{Introduction}

Sialic acid is an acidic monosaccharide and is expressed most frequently at the end of glycan chains to provide a negative charge on the cell surface. The two most prevalent species of sialic acids existing in nature are \textit{N}-acetylneuraminic acid (Neu5Ac) and \textit{N}-glycolyneuraminic acid (Neu5Gc) [1,2,3]. Neu5Ac is abundantly contained in the mammalian brain and plays crucial roles in many neural functions such as memory, synaptic plasticity, brain development and...
neurological disorder [4,5,6]. In contrast, Neu5Gc is synthesized via the effect of cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH), which catalyzes the conversion of cytidine 5'-monophosphate Neu5Ac (CMP-Neu5Ac) to CMP-Neu5Gc [7]. Since mRNA of CMAH is not expressed in the mammalian brain, Neu5Gc exists in the brain only at a trace level [7,8,9,10]. Although humans are unable to synthesize Neu5Gc due to a CMAH gene mutation, Neu5Gc expression has been reported in normal human cells and various human cancer cells [1,11,12,13,14]. Neu5Gc is contained in foods, especially in red meat [12,15]. Neu5Gc from dietary sources ingested into humans is incorporated into newly synthesized glycoproteins [11].

Sialidase, which removes sialic acid residues from sialylglycoconjugates, generally cleaves Neu5Ac residues more preferentially than Neu5Gc residues [8,16]. We reported the catalytic preference of Salmonella typhimurium LT2 sialidase for Neu5Ac residues over Neu5Gc residues [17]. Thus, sialyl signalling controlled by sialidase receives a competitive influence of Neu5Gc. Polysialic acid (PSA) plays crucial roles in hippocampal synaptic plasticity, memory and brain development [18,19,20,21,22]. Since α2-8-linked Neu5Gc incorporated into PSA resists sialidase breakdown, it has been assumed that even a small amount of Neu5Gc is harmful for brain functions [8]. However, in vivo kinetics of Neu5Gc in the whole body, especially in the brain, remains poorly understood.

To determine the in vivo kinetics of Neu5Gc, we synthesized 14C-Neu5Gc from 14C-sodium pyruvate and N-glycolylmannosamine using N-acetylneuraminic acid aldolase. The in vivo kinetics of 14C-Neu5Gc in a rat’s whole body was investigated after tail vein injection and compared to that of 14C-Neu5Ac. Since 14C-Neu5Gc was detected in the brain after tail vein injection, detailed distribution of 14C-Neu5Gc in the brain was imaged using autoradiography. Additionally, since 14C-Neu5Gc was accumulated in the brain more preferentially than was 14C-Neu5Ac, the in vivo kinetics of 14C-Neu5Gc after intraventricular injection was compared to that of 14C-Neu5Ac.

### Materials and Methods

#### Experimental animals

Male Wistar rats (8 weeks old, 166–179 g in b.w.) were purchased from Japan SLC (Shizuoka, Japan). They were housed under standard laboratory conditions (23 ± 1°C, 55 ± 5% humidity) and had access to tap water and diet ad libitum. The lights were automatically turned on at 8:00 and off at 20:00.

#### Statement on animal welfare

The animals were cared for in accordance with the guidelines established by the University of Shizuoka. All animal experiments were pre-approved by the Animal Ethics Committee of the University of Shizuoka.

#### Synthesis of 14C-Neu5Gc

14C-Neu5Gc was enzymatically synthesized from 250 μmol sodium pyruvate, 1.85 MBq (or 27.8 MBq for autoradiography) [1-14C]-sodium pyruvate (352 MBq/mmole, PerkinElmer) and 300 μmol ManNGc using 1.0 U N-acetylneuraminic acid aldolase from Escherichia coli (Nacalai tesque) [23]. The reactants were incubated at 37°C for 48 hours in 200 μl of 20 mM phosphate buffer (pH 7.4). After filtration using an ultrafiltration membrane (30 kDa cut-off, Merck Millipore), the product was applied to a column filled with 50 ml of anion exchange resin (Dowex 1x8, 200–400 mesh, HCOO− form). ManNGc was washed out with 5 bed
volumes of water, and then Neu5Gc was eluted with 10 bed volumes of 0.3 M formic acid. The fractions containing Neu5Gc were determined by Ehrlich’s reagent and concentrated by a rotary evaporator (Tokyo Rikakikai) and vacuum freeze drying equipment (Tokyo Rikakikai). 14C-Neu5Ac was synthesized from ManNAc by incubating for 24 hours and purifying in the same way. The fractions were shown to have a single radioactive peak by assaying with thin layer chromatography (TLC) using propanol/acetic acid/water (60:10:25) as the mobile phase. The yields of 14C-Neu5Gc and 14C-Neu5Ac were determined by using a liquid scintillation cocktail (Hionic-Fluor, PerkinElmer) and a liquid scintillation counter (LSC) (LSC-3100, Aloka) to be 19.5% and 34.1%, respectively. They were dissolved in 200 mM phosphate buffer and stored at −30°C.

Measurement of radioactivity in each organ
14C-Neu5Gc or 14C-Neu5Ac (50 kBq/170 g of body weight) in 200 μl of 200 mM phosphate buffer was injected into rat tail veins. One, 3 or 24 hours after the injection, the rats were anesthetized with chloral hydrate (70 mg/kg). After collection of blood and urine, rats were transcardially perfused with phosphate buffered saline (PBS, pH 7.4) to remove blood from the whole body. Each sample (50–200 mg) of urine, blood and organs including the kidney, liver, lung, spleen, heart, left cerebral hemisphere, right hippocampus and right cerebellar hemisphere was dissolved in 1 ml of SOLVABLE (PerkinElmer) overnight at 50°C, and 0.5 ml of isopropanol and 0.5 ml of hydrogen peroxide were added. After addition of liquid scintillation cocktail (10 ml, Hionic Flour, PerkinElmer), radioactivities were measured using the LSC [24]. Total amounts of radioactivity in each whole organ were calculated from their volume or weights. The total blood volume was estimated from body weight (60 ml/kg B.W.). The total weights of the brain, hippocampus and cerebellum were estimated from hemisphere or unilateral weights.

Brain autoradiography
Three hours after injection of 14C-Neu5Gc (1.0 MBq/170 g of body weight, 200 μl) or 14C-Neu5Ac (1.0 MBq/170 g of body weight, 200 μl) into a tail vein, the rats were transcardially perfused with PBS under anesthesia. The brains were removed and used for autoradiography and ganglioside analysis. For the autoradiography [25], the brains were embedded into ice-cold 4% sodium carboxymethyl cellulose and frozen at −30°C. Serial coronal brain sections were cut into 400-μm-thick sections at −15°C with a cryotome (Cryotome CR-502, Nakagawa) and dried at −30°C. After exposure to imaging plates (Storage Phosphor Screen BAS-IP SR 2025E, 20 cm × 25 cm, GE Healthcare) for 2 months, distribution of radioactivity in each section was determined using an autoradiographic scanner (Typhoon 9400, GE Healthcare).

Measurement of radioactivity in each ganglioside
Total lipid and protein fractions were separated from whole brain homogenate by the Folch and the Bligh and Dyer (B/D) extraction methods using a monophasic solution of chloroform/methanol/water (C/M/W) [26]. Briefly, the brain was homogenized in water equal to 1.5 times of homogenate volume. The homogenate (0.1 mL) was mixed with 2.25 ml of chloroform/methanol (C/M, 2:1, v/v) and incubated at 37°C for 60 min with constant shaking. After adding 650 μl of methanol, the mixture was centrifuged (3,000 × g) at 4°C for 30 min and the supernatant was removed. The residue was extracted again with 500 μl of C/M/W (5:10:4, v/v/v) at 37°C for 30 min and centrifuged (3,000 × g) at 4°C for 30 min. The two extracts were combined, evaporated with a centrifugal evaporator, and used as the lipid fraction. The residue was used as the chloroform-methanol insoluble fraction including proteins.
For ganglioside analysis, the lipid fractions were redissolved in 5 ml of C/M (9:1, v/v) and applied to a phenyl sepharose column (2 ml, Phenyl Sepharose CL-4B, Sigma-Aldrich) equilibrated with C/M (9:1, v/v) [27]. After elution of most neutral lipids and phospholipids with 10 ml of C/M (9:1, v/v) and 10 ml of C/M (85:15, v/v), gangliosides were eluted with 10 ml of C/M (1:1, v/v) and 10 ml of methanol. Each fraction was redissolved in 50 μl of C/M (2:1, v/v). Gangliosides were separated by high-performance thin layer chromatography (HPTLC, Merck Millipore) using C/M/0.25% CaCl2 (50:40:10, v/v/v) and visualized with resorcinol/HCl reagent [28]. The ganglioside spots were scratched and extracted with 200 μl/mg of C/M/W (10:10:1, v/v/v). The radioactivity in each fraction was measured in the same manner as that described above.

Intraventricular injection

Under anaesthesia, 5 μl of 14C-Neu5Gc or 14C-Neu5Ac (125 Bq/240 g of body weight) was injected into the right lateral ventricle (AP = −1.0 mm; ML = 1.9 mm; DV = 3.8 mm) [29] through a cannula using a stereotaxic instrument (Narishige). One, 3 or 24 hours after the injection, the rats were transcardially perfused with PBS after blood collection. The radioactivity in the right hippocampus, left hemisphere and blood was measured in the same manner as that described above.

Statistical analysis

Statistical significance was assessed using a two-tailed unpaired Student’s t-test or two-way ANOVA, followed by Bonferroni’s multiple comparison test. Statistical analysis was performed using Prism 5 (GraphPad). Error bars are expressed as standard errors of the mean.

Results

We synthesized radioisotope-labeled Neu5Gc (14C-Neu5Gc) by using N-glycolylmannosamine, 14C-pyruvic acid and sialic acid aldolase (EC 4.1.3.3, also called sialic acid lyase) under optimum reaction conditions that were determined using unlabeled sodium pyruvate (data not shown). The yield of 14C-Neu5Gc was 19.5%, while that of 14C-Neu5Ac synthesized using N-acetylmannosamine was 34.1%. After purification by an anion exchange resin, single radioactive bands of 14C-Neu5Gc and 14C-Neu5Ac were detected by autoradiography in TLC (Fig 1A and 1B).

To determine the in vivo kinetics of Neu5Gc in the rat whole body, the distribution of 14C-Neu5Gc was investigated after 14C-Neu5Gc injection into a tail vein. Most of the radioactivity was detected in urine (Fig 2A). Radioactivity in the blood and organs including the kidney, liver, lung, spleen and heart was detected at 1 hr after 14C-Neu5Gc injection and decreased over a period of 24 hr. Radioactivity was also detected in the brain after tail vein injection of 14C-Neu5Gc (Fig 2A). The whole body distribution of radioactivity in the 14C-Neu5Gc-injected rat was similar to that in the 14C-Neu5Ac-injected rat (Fig 2B).

To investigate the difference between in vivo kinetics of Neu5Gc and that of Neu5Ac in the brain, radioactivity of 14C-Neu5Gc and that of 14C-Neu5Ac were compared after tail vein injection. After 14C-Neu5Gc injection, radioactivity in the brain reached a maximum level at 3 hr. In contrast, radioactivity after 14C-Neu5Ac injection reached a plateau in less than 1 hr and did not significantly change over a period of 24 hr (Fig 3A). 14C-Neu5Gc showed preferential accumulation over 14C-Neu5Ac in the brain and hippocampus (Fig 3A and 3B). In the cerebellum and blood, the amounts of 14C-Neu5Gc and 14C-Neu5Ac were not significantly different (Fig 3C and 3D).
By using autoradiography, we next determined the detailed distribution of radioactivity in the brain at 3 hr after tail vein injection of $^{14}\text{C}$-Neu5Gc. Although radioactivity was detected from all observed brain regions including the olfactory bulb, striatum, thalamus, periaqueductal gray, cerebellum and medulla, the hippocampus showed intense radioactivity (Fig 4). A similar tendency was obtained by radioactivity quantification. The hippocampus (8.94 ± 3.28 Bq/g tissue) showed higher radioactivity than that of the cerebellum (4.73 ± 0.50 Bq/g tissue) after $^{14}\text{C}$-Neu5Gc injection. In the case of $^{14}\text{C}$-Neu5Ac, radioactivity was also detected from all observed brain regions, but its signal intensity was weak compared to that of $^{14}\text{C}$-Neu5Gc (Fig 4). Radioactivity in the hippocampus (2.76 ± 0.31 Bq/g tissue) after $^{14}\text{C}$-Neu5Ac injection was also higher than that in the cerebellum (2.31 ± 0.31 Bq/g tissue).

To determine whether $^{14}\text{C}$-Neu5Gc transferred from blood to the brain is used for a component of sialylglycoconjugates such as glycolipids and glycoproteins, we measured radioactivity levels in chloroform-methanol soluble and insoluble fractions derived from the brain after $^{14}\text{C}$-Neu5Gc injection into a tail vein. Although radioactivity was detected in both fractions, the chloroform-methanol soluble fraction (lipid fraction) showed higher radioactivity than that of the chloroform-methanol insoluble fraction including proteins (Fig 5A). In both fractions, radioactivity after $^{14}\text{C}$-Neu5Gc injection was higher than that after $^{14}\text{C}$-Neu5Ac injection.

To obtain direct evidence that $^{14}\text{C}$-Neu5Gc was used as a component of glycolipids, gangliosides in the lipid fraction were separated using hydrophobic interaction chromatography and
were analyzed for radioactivity. After applying the lipid fraction onto a phenyl sepharose column, the column was washed with C/M (9:1, fraction 1) and C/M (85:15, fraction 2). After elution with C/M (1:1, fraction 3) and methanol (fraction 4), gangliosides were separated by TLC and detected with resorcinol/HCl reagent. Fractions 3 and 4 contained large amounts of gangliosides, and intense radioactivity was detected (Fig 5B and 5C). Next, gangliosides in fractions 3 and 4 were separated precisely using HPTLC (Fig 5D). As a result of radioactivity measurement in each ganglioside, radioactivity was detected from all of the measured gangliosides including GM1, GD1a, GD1b, GT1b and GQ1b (Fig 5E and 5F). In the case of 14C-Neu5Ac injection, radioactivity was also detected from all of the measured gangliosides. Radioactivity derived from proteins in the chloroform-methanol insoluble fraction was also analyzed by Western blotting, but the radioactivity was too low to be detected by autoradiography (data not shown).

To investigate in more detail the kinetics of Neu5Gc in the brain, the elimination of 14C-Neu5Gc was compared to that of 14C-Neu5Ac. After intracerebroventricular injection of 14C-Neu5Gc and 14C-Neu5Ac into the lateral ventricle, radioactivity levels decreased over a period of 24 hr in the brain hemisphere and hippocampus (Fig 6A and 6B). Radioactivity levels in the brain hemisphere and hippocampus after 14C-Neu5Gc injection were significantly higher than those after 14C-Neu5Ac injection. Radioactivity was also detected in the blood after intracerebroventricular injection of 14C-Neu5Gc and 14C-Neu5Ac (Fig 6C).
Fig 3. Preferential accumulation of $^{14}$C-Neu5Gc over $^{14}$C-Neu5Ac in the brain. Radioactivities in the brain (A), hippocampus (B), cerebellum (C) and blood (D) at 1, 3 and 24 hr after tail vein injection of $^{14}$C-Neu5Gc ($n = 5$) or $^{14}$C-Neu5Ac ($n = 5–6$) are shown as relative values to the radioactivities of injected-$^{14}$C-Neu5Gc or $^{14}$C-Neu5Ac. *$P < 0.05$ and ***$P < 0.001$. of $^{14}$C-Neu5Gc or $^{14}$C-Neu5Ac.

Fig 4. Autoradiograms of $^{14}$C-Neu5Gc and $^{14}$C-Neu5Ac in the brain after tail vein injection. Autoradiography of the rat brain was performed at 3 hours after tail vein injection of $^{14}$C-Neu5Gc (A) or $^{14}$C-Neu5Ac (B). The experiment was performed twice, and the autoradiograms obtained were almost identical. O, olfactory bulb; S, striatum; H, hippocampus; T, thalamus; P, periaqueductal gray; C, cerebellum; M, medulla. Scale bar, 5 mm.

doi:10.1371/journal.pone.0131061.g004
Fig 5. Incorporation of $^{14}$C-Neu5Gc into gangliosides in the brain after tail vein injection. (A) Three hr after tail vein injection of $^{14}$C-Neu5Gc ($n = 3$) or $^{14}$C-Neu5Ac ($n = 3$), chloroform-methanol soluble (S) and insoluble (I) fractions (Fr.) were obtained from the rat brain and radioactivity was measured. N.D., not detected. **$P < 0.001$. (B) After applying the lipid fraction onto a phenyl sepharose column, the column was washed with C/M (9:1, fr. 1) and C/M (85:15, fr. 2), and then gangliosides were eluted with C/M (1:1, fr. 3) and methanol (fr. 4). Gangliosides in each fraction were analyzed by TLC. (C) The radioactivity in each fraction is shown as a relative value to the total radioactivities in all four fractions ($^{14}$C-Neu5Gc, $n = 3$; $^{14}$C-Neu5Ac, $n = 3$). (D) Gangliosides were separated by HPTLC using C/M/0.25% CaCl$_2$ (50:40:10, v/v/v) and visualized with resorcinol/HCl reagent. (E and F) Radioactivities in each band are shown as relative values to the total radioactivities in fr. 3 (E, $n = 3$) or fr. 4 (F, $n = 4$).

doi:10.1371/journal.pone.0131061.g005

Fig 6. Excretion of $^{14}$C-Neu5Gc and $^{14}$C-Neu5Ac after intracerebroventricular injection. Radioactivities in the right brain hemisphere (A), the left hippocampus (B) and blood (C) at 1, 3 and 24 hr after right lateral ventricle injection of $^{14}$C-Neu5Gc ($n = 5$) or $^{14}$C-Neu5Ac ($n = 5$) are shown as relative values to the radioactivities of injected $^{14}$C-Neu5Gc or $^{14}$C-Neu5Ac. *$P < 0.05$ and **$P < 0.01$.

doi:10.1371/journal.pone.0131061.g006
Discussion

The *in vivo* kinetics of Neu5Gc in the rat whole body was investigated using synthesized $^{14}$C-Neu5Gc. Although most of $^{14}$C-Neu5Gc was excreted in urine after tail vein injection, a small amount of $^{14}$C-Neu5Gc was detected in the brain. This result indicates that Neu5Gc is transferred into the brain across the blood brain barrier. $^{14}$C-Neu5Gc was also detected in other organs including the kidney, liver, lung, spleen and heart. The *in vivo* kinetics of $^{14}$C-Neu5Gc in the rat whole body except for the brain was approximately consistent with the results of a previous study [30].

Mammalian N-acetylneuraminic acid aldolase cleaves not only Neu5Ac but also Neu5Gc [31]. To exclude the possibility that radioactivity detected in the brain was caused by the $^{14}$C-Neu5Gc cleavage product produced by endogenous enzymes such as N-acetylneuraminic acid aldolase, we analyzed the radioactivity in sialylglycoconjugates in brains after tail vein injection of $^{14}$C-Neu5Gc. Since radioactivity was detected in both chloroform-methanol soluble and insoluble fractions, $^{14}$C-Neu5Gc would be contained in the brains as components of glycolipids and glycoproteins. Radioactivity was much higher in the lipid fraction than in the chloroform-methanol insoluble fraction including proteins, indicating that Neu5Gc was preferentially used in glycolipids. Results of radioactivity measurements in gangliosides contained in the lipid fraction showed that GM1, GD1a, GD1b, GT1b and GQ1b had radioactivity. Because free Neu5Gc is taken up by mammalian cells via pinocytosis and is metabolically incorporated into glycoconjugates [32], Neu5Gc transferred to the brain would also be taken up by cells and incorporated into gangliosides.

We also compared the accumulation of Neu5Gc with that of Neu5Ac in brain after tail vein injection. $^{14}$C-Neu5Gc accumulated in the brain and hippocampus more abundantly than did Neu5Ac. Abundant accumulation of Neu5Gc in the brain was also confirmed by using autoradiography. Because the reduction of $^{14}$C-Neu5Gc in the brain and hippocampus was slower than that of $^{14}$C-Neu5Ac after intracerebroventricular infusion, abundant accumulation of Neu5Gc would be caused by the slow elimination of Neu5Gc from the brain and hippocampus. The rate of hydrolysis of Neu5Gc by sialidase and N-acetylneuraminic acid aldolase is slower than that of Neu5Ac. Actually, the amounts of $^{14}$C-Neu5Gc in lipid and protein fractions were larger than those of $^{14}$C-Neu5Ac. Thus, one reason for the persistence of Neu5Gc may be slow elimination by, for example, sialidases. To obtain a better understanding of the different kinetics of Neu5Gc and Neu5Ac, comparison of the catabolic, anabolic and transport efficiency in the brain will be needed.

The brain-specific suppression of Neu5Gc expression, which is a common feature in mammals, may suggest that Neu5Gc has toxicity against brain functions. Our brain imaging of $^{14}$C-Neu5Gc after tail vein injection by autoradiography indicated that Neu5Gc transferred from blood is highly accumulated in the hippocampus. In the hippocampus, it has been reported that sialyl signalling via gangliosides such as GQ1b and PSA, which bind to neural cell adhesion molecule (NCAM), is necessary for synaptic plasticity and memory [33,34,35]. Sialidase also plays important roles in many neural functions, including neural excitation, axonal elongation, differentiation and maturation [5,36]. Four types of mammalian sialidase (Neu1, Neu2, Neu3 and Neu4) have been identified in mammalian tissues by their localization and enzymatic properties. Shiozaki et al. reported that Neu4 mRNA was expressed abundantly in the hippocampus [37]. We previously found by using a highly sensitive fluorescent histochemical method that the hippocampus, especially in the regions where mossy fiber terminals exist, showed intense sialidase activities [38,39]. Since the cleavage of Neu5Gc by sialidase is much less than that of Neu5Ac, competitive inhibition of sialidase with Neu5Gc may disrupt the regulation of sialyl signalling in the hippocampus.
Author Contributions
Conceived and designed the experiments: AM TS. Performed the experiments: RT AM YM. Analyzed the data: TT. Contributed reagents/materials/analysis tools: TO KI. Wrote the paper: RT AM TS.

References
1. Inoue S, Sato C, Kitajima K. Extensive enrichment of N-glycolyneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology. 2010; 20: 752–762. doi:10.1093/glycob/cwq030 PMID: 20197272
2. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol. 2009; 19: 507–514. doi:10.1016/j.sbi.2009.06.003 PMID: 19699080
3. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconjug J. 2009; 26: 231–245. doi:10.1007/s10719-008-9183-z PMID: 18777136
4. Schütz RL, Gerardy-Schahn R, Hildebrandt H. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev. 2014; 94: 461–518. doi:10.1152/physrev.00033.2013 PMID: 24692554
5. Minami A, Suzuki T. Distribution of sialidase activity and the role of sialidase in the brain. Trends Glycosci Glycotech. 2012; 24: 112–121.
6. Wang B. Sialic acid is an essential nutrient for brain development and cognition. Annu Rev Nutr. 2009; 29: 177–222. doi: 10.1146/annurev.nutr.28.061807.155515 PMID: 19575597
7. Kawano T, Koyama S, Takekatsu H, Kozutsumi Y, Kawasaki H, Kawashima S, et al. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolyneuraminic acid. J Biol Chem. 1995; 270: 16458–16463. PMID: 7608218
8. Davies LR, Pearce OM, Tessier MB, Assar S, Smutova V, Pajunen M, et al. Metabolism of vertebrate amino sugars with N-glycolyl groups: resistance of alpha2-8-linked N-glycolyneuraminic acid to enzymatic cleavage. J Biol Chem. 2012; 287: 28917–28931. doi:10.1074/jbc.M112.365056 PMID: 22692207
9. Nakamura K, Hashimoto Y, Yamakawa T, Suzuki A. Genetic polymorphism of ganglioside expression in mouse organs. J Biochem. 1988; 103: 201–208. PMID: 3360761
10. Song KH, Kang YJ, Jin Uh, Park Yi, Kim SM, Seong HH, et al. Cloning and functional characterization of pig CMP-N-acetylneuraminic acid hydroxylase for the synthesis of N-glycolyneuraminic acid as the xenograft antigenic determinant in pig-human xenotransplantation. J Biol Chem. 2010; 427: 179–188. doi: 10.1042/BJ20090835 PMID: 20047559
11. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003; 100: 12045–12050. PMID: 14523234
12. Samraj AN, Pearce OM, Laubli H, Crittenden AN, Bergfeld AK, Banda K, et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A. 2015; 112: 542–547. doi:10.1073/pnas.1417508112 PMID: 25548184
13. Samraj AN, Laubli H, Varki N, Varki A. Involvement of a non-human sialic acid in human cancer. Front Oncol. 2014; 4: 33. doi: 10.3389/fonc.2014.00033 PMID: 24600589
14. Diaz SL, Padler-Karavani V, Ghaderi D, Hurtado-Ziola N, Yu H, Chen X, et al. Sensitive and specific detection of the non-human sialic Acid N-glycolyneuraminic acid in human tissues and biotherapeutic products. PLoS One. 2009; 4: e4241. doi: 10.1371/journal.pone.0004241 PMID: 19156207
15. Chen Y, Pan L, Liu N, Troy FA, Wang B. LC-MS/MS quantification of N-acetylneuraminic acid, N-glycolyneuraminic acid and ketodeoxynulosonic acid levels in the urine and potential relationship with dietary sialic acid intake and disease in 3- to 5-year-old children. Br J Nutr. 2014; 111: 332–341. doi: 10.1017/S0007114513002468 PMID: 23915700
16. Corfield AP, Veh RW, Wember M, Michalski JC, Schauer R. The release of N-acetyl- and N-glycoloylneuraminic acid from soluble complex carbohydrates and erythrocytes by bacterial, viral and mammalian sialidases. Biochem J. 2013; 1981; 197: 293–299. PMID: 7325957
17. Minami A, Ishibashi S, Ikeka K, Ishitsubo E, Hori T, Tokiwa H, et al. Catalytic preference of Salmonella typhimurium LT2 sialidase for N-acetylneuraminic acid residues over N-glycolyneuraminic acid residues. FEBS Open Bio. 2013; 3: 231–236. doi: 10.1016/j.fob.2013.05.002 PMID: 23772399
18. Eckhardt M, Bukalo O, Chazal G, Wang L, Goridis C, Schachner M, et al. Mice deficient in the polysialyltransferase ST8SiaIV/PST-1 allow discrimination of the roles of neural cell adhesion molecule protein
and polysialic acid in neural development and synaptic plasticity. J Neurosci. 2000; 20: 5234–5244. PMID: 10884307

19. Muller D, Wang C, Skibo G, Toni N, Cremer H, Calaora V, et al. PSA-NCAM is required for activity-induced synaptic plasticity. Neuron. 1996; 17: 413–422. PMID: 8816705

20. Di Cristo G, Chattopadhayya B, Kuhlman SJ, Fu Y, Belanger MC, Wu CZ, et al. Activity-dependent PSA expression regulates inhibitory maturation and onset of critical period plasticity. Nat Neurosci. 2007; 10: 1569–1577. PMID: 18026099

21. Senkov O, Tikhobrazova O, Dityatev A. PSA-NCAM: synaptic functions mediated by its interactions with proteoglycans and glutamate receptors. Int J Biochem Cell Biol. 2012; 44: 591–595. doi: 10.1016/j.biocel.2012.01.008 PMID: 22300986

22. Bonfanti L. PSA-NCAM in mammalian structural plasticity and neurogenesis. Prog Neurobiol. 2006; 80: 129–164. PMID: 17029752

23. Nöhle U, Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, 14C- and 3H-labeled N-acetylneuraminic acid mixture in the mouse and rat. Hoppe Seylers Z Physiol Chem. 1981; 362: 1495–1506. PMID: 7030915

24. Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, et al. Novel DDS strategy, "dual-targeting", and its application for anti-neovascular therapy. Cancer Lett. 2010; 287: 165–171. doi: 10.1016/j.canlet.2009.06.008 PMID: 19616372

25. Takeda A, Tamano H, Enomoto S, Oku N. Zinc-65 imaging of rat brain tumors. Cancer Res. 2001; 61: 5065–5069. PMID: 11431342

26. Ando S. (1990) Lipid III (glycolipid): extraction, separation and purification. In: Society TJB, editor. Shin seikagaku jikken kouza. Tokyo, Japan: Tokyo kagaku dojin. pp. 37–66.

27. Waki H, Kon K, Tanaka Y, Ando S. Facile methods for isolation and determination of gangliosides in a small scale: age-related changes of gangliosides in mouse brain synaptic plasma membranes. Anal Biochem. 1994; 222: 156–162. PMID: 7856842

28. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996; 56: 5165–5171. PMID: 8912852

29. Paxinos G, Watson C. (2007) The rat brain in stereotaxic coordinates. Amsterdam; Boston;: Academic Press/Elsevier. 1 v. (unpaged) p.

30. Nöhle U, Beau JM, Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat. Eur J Biochem. 1982; 126: 543–548. PMID: 7140746

31. Schauer R, Wember M. Isolation and characterization of sialate lyase from pig kidney. Biol Chem Hoppe Seyler. 1996; 377: 293–299. PMID: 8828820

32. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 2005; 280: 4228–4237. PMID: 15557321

33. Jung WR, Kim HG, Kim KL. Ganglioside GQ1b improves spatial learning and memory of rats as measured by the Y-maze and the Morris water maze tests. Neurosci Lett. 2008; 439: 220–225. doi: 10.1016/j.neulet.2008.05.020 PMID: 18514410

34. Furuse H, Waki H, Kaneko K, Fuji S, Miura M, Sasaki H, et al. Effect of the mono- and tetra-sialogangliosides, GM1 and GQ1b, on long-term potentiation in the CA1 hippocampal neurons of the guinea pig. Exp Brain Res. 1998; 123: 307–314. PMID: 9860269

35. Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H, Schachner M. The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res. 1996; 45: 143–152. PMID: 8843031

36. Miyagi T, Yamaguchi K. Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology. 2012; 22: 880–896. doi: 10.1093/glycob/cws057 PMID: 22377912

37. Shiozaki K, Koski K, Yamaguchi K, Shiozaki M, Narimatsu H, Miyagi T. Developmental change of sialidase neu4 expression in murine brain and its involvement in the regulation of neuronal cell differentiation. J Biol Chem. 2009; 284: 21157–21164. doi: 10.1074/jbc.M109.127080 PMID: 19506080

38. Minami A, Otsubo T, Ieno D, Ikeda K, Kanazawa H, Shimizu K, et al. Visualization of sialidase activity in Mammalian tissues and cancer detection with a novel fluorescent sialidase substrate. PLoS One. 2014; 9: e81941. doi: 10.1371/journal.pone.0081941 PMID: 24427265

39. Minami A, Shimizu H, Meguro Y, Shibata N, Kanazawa H, Ikeda K, et al. Imaging of sialidase activity in rat brain sections by a highly sensitive fluorescent histochemical method. Neuroimage. 2011; 58: 34–40. doi: 10.1016/j.neuroimage.2011.06.017 PMID: 21703353